Spin Disorder and Magnetic Anisotropy in Fe3O4 Nanoparticles

We have studied the magnetic behavior of dextran-coated magnetite (Fe$_3$O$_4$) nanoparticles with median particle size \left=8 $nm$. Magnetization curves and in-field M\"ossbauer spectroscopy measurements showed that the magnetic moment $M_S$ of the particles was much smaller than the bulk material. However, we found no evidence of magnetic irreversibility or non-saturating behavior at high fields, usually associated to spin canting. The values of magnetic anisotropy $K_{eff}$ from different techniques indicate that surface or shape contributions are negligible. It is proposed that these particles have bulk-like ferrimagnetic structure with ordered A and B sublattices, but nearly compensated magnetic moments. The dependence of the blocking temperature with frequency and applied fields, $T_B(H,\omega)$, suggests that the observed non-monotonic behavior is governed by the strength of interparticle interactions.Comment: 11 pages, 7 figures, 3 Table

Stochastic blockmodels and community structure in networks

Stochastic blockmodels have been proposed as a tool for detecting community structure in networks as well as for generating synthetic networks for use as benchmarks. Most blockmodels, however, ignore variation in vertex degree, making them unsuitable for applications to real-world networks, which typically display broad degree distributions that can significantly distort the results. Here we demonstrate how the generalization of blockmodels to incorporate this missing element leads to an improved objective function for community detection in complex networks. We also propose a heuristic algorithm for community detection using this objective function or its non-degree-corrected counterpart and show that the degree-corrected version dramatically outperforms the uncorrected one in both real-world and synthetic networks.Comment: 11 pages, 3 figure

Evidence of random magnetic anisotropy in ferrihydrite nanoparticles based on analysis of statistical distributions

We show that the magnetic anisotropy energy of antiferromagnetic ferrihydrite depends on the square root of the nanoparticles volume, using a method based on the analysis of statistical distributions. The size distribution was obtained by transmission electron microscopy, and the anisotropy energy distributions were obtained from ac magnetic susceptibility and magnetic relaxation. The square root dependence corresponds to random local anisotropy, whose average is given by its variance, and can be understood in terms of the recently proposed single phase homogeneous structure of ferrihydrite.Comment: 6 pages, 2 figure

Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis

OBJECTIVES: To compare the efficacy and safety of bimekizumab 160 mg every 4 weeks, a selective inhibitor of interleukin‑17F and 17A, with biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS). METHODS: A systematic literature review identified randomised controlled trials until January 2023 for inclusion in Bayesian network meta-analyses (NMAs), including three b/tsDMARDs exposure networks: predominantly-naïve, naïve, and experienced. Outcomes were Assessment of SpondyloArthritis international Society (ASAS)20, ASAS40, and ASAS partial remission (PR) response rates at 12-16 weeks. A safety NMA investigated discontinuations due to any reason and serious adverse events at 12-16 weeks. RESULTS: The NMA included 36 trials. The predominantly-naïve network provided the most comprehensive results. In the predominantly-naïve nr-axSpA analysis, bimekizumab had significantly higher ASAS20 response rates vs secukinumab 150 mg (with loading dose [LD]/without LD), and comparable response rates vs other active comparators. In the predominantly-naïve AS analysis, bimekizumab had significantly higher ASAS40 response rates vs secukinumab 150 mg (without LD), significantly higher ASAS-PR response rates vs secukinumab 150 mg (with LD), and comparable response rates vs other active comparators. Bimekizumab demonstrated similar safety to other b/tsDMARDs. CONCLUSION: Across ASAS outcomes, bimekizumab was comparable to most b/tsDMARDs, including ixekizumab, TNF inhibitors and upadacitinib, and achieved higher response rates vs secukinumab for some ASAS outcomes in predominantly b/tsDMARD-naïve nr-axSpA and AS patients at 12-16 weeks. In a pooled axSpA network, bimekizumab demonstrated comparable safety vs other b/tsDMARDs